Drug Monitoring - Methods
Research News and Information

Monday, November 23, 2009

High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration.

29 Sep 2009 Insulin-like growth factor-I (IGF-I) is a known biomarker of recombinant human growth hormone (rhGH) abuse, and is also used clinically to confirm acromegaly. The protein leucine-rich alpha-2-glycoprotein (LRG) was recently identified as a putative ... Read more...

Prevention of sternal wound infections after coronary artery bypass graft surgery with use of insulin drug therapy: a review of the literature.

30 Aug 2009 Diabetes is a disease that can increase the risks of developing cardiac problems, which can include coronary artery bypass graft surgery. These patients are at an increased risk of developing serious complications after this surgery, including deep ... Read more...

Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.

30 Aug 2009 BACKGROUND: Sitagliptin is recommended for initial and maintenance dosing at 100 mg daily. Downward dose adjustment is recommended in patients with moderate or severe renal insufficiency. OBJECTIVE: To determine the prevalence of the potentially ... Read more...

Latest indexed articles for 'Drug Monitoring - Methods'

These are the very latest articles for this heading:

• Monitoring and evaluation of PEPFAR treatment programmes. Oct 2009
• High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. 29 Sep 2009
• Prevention of sternal wound infections after coronary artery bypass graft surgery with use of insulin drug therapy: a review of the literature. 30 Aug 2009
• Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. 30 Aug 2009
• Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. 16 Aug 2009
• A benchmark for platelet count monitoring with low-molecular-weight heparin: expanding implementation of National Patient Safety Goals. 16 Aug 2009
• Erythrocyte methotrexate-polyglutamate assay using fluorescence polarization immunoassay technique: application to the monitoring of patients with rheumatoid arthritis. 30 Jul 2009
• Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial. 30 Jul 2009
• New drug, fospropofol disodium: a propofol prodrug. 30 Jul 2009
• Frontal lobe oxygenation is maintained during hypotension following propofol-fentanyl anesthesia. 30 Jul 2009
• Improving cost-effectiveness of and outcomes from drug therapy in patients with atrial fibrillation in managed care: role of the pharmacist. 30 Jul 2009
• Pharmacologic management of atrial fibrillation: established and emerging options. 30 Jul 2009
• Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. 30 Jul 2009
• Diagnostic value of T-cell monitoring assays in kidney transplantation. 30 Jul 2009
• Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants. 30 Jul 2009
• Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. 30 Jul 2009
• Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. 30 Jul 2009
• Recent developments in the use of oral anticoagulants. 30 Jul 2009
• Overview of insulin replacement therapy. 30 Jul 2009
• When and how to implement basal-bolus therapy: treating to success. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Drug Monitoring'

Definition: The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.

Descriptor UI: D016903

Alternative terms: Drug Monitoring; Monitoring, Drug; Therapeutic Drug Monitoring; Drug Monitoring, Therapeutic; Monitoring, Therapeutic Drug;

Related Mesh Headings: Adverse Drug Reaction Reporting Systems;

Allowable Qualifiers: adverse effects; classification; economics; history; instrumentation; methods; mortality; nursing; psychology; standards; trends; utilization; veterinary; statistics & numerical data; contraindications; ethics;

Tree Number: E01.370.520.200;

History Note: 92